drugset
drugset / Trial / NCT00216489

A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)

NCT00216489 ↗

Phase 4 Completed 191 enrolled Janssen Cilag Pharmaceutica S.A.C.I., Greece
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to confirm the safety and effectiveness of rabeprazole in the treatment of patients with erosive or ulcerative gastroesophageal reflux disease (GERD) in routine primary health care.

Timeline

Start
2003-03
Primary completion
—
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Rabeprazole Small molecule 20 mg —
Subject Rabeprazole Small molecule 40 mg —

Indications

dyspepsia gastroesophageal reflux disease